Staff Profile

Professor Greystoke joined Newcastle University and the Northern Centre for Cancer Care in 2014 after 8 years spent at the University of Manchester/ Christie NHS Trust.  He is one of 4 consultants that run the Sir Bobby Robson Early Clinical Trials Centre at the Freeman hospital in Newcastle,and has a special interest in the development of new anti-cancer drugs for patients with lung cancer. He leads systemic therapy research for NSCLC in the North-East, with a portfolio of Phase I-IV studies. In addition he is the Clinical Director for Cancer for the Yorkshire, Hull and North East England Genomic Medicine Service and led the NHSE pilot assessing the cost-effectiveness of cfDNA in patients presenting with advanced lung cancer. He is the Joint Chief Investigator of the CONCORDE platform (adding in new drugs to radical radiotherapy in lung cancer), and leads the Pharmacodynamic Biomarker team at Newcastle University Cancer

Areas of expertise

• Lung Cancer
• Early Drug development
• Personalised Medicine
• Circulating Biomarkers
• Treatment of cancer in the elderly

Google Scholar: Click here.

• Articles

  • Norris RP, Fuller E, Greystoke A, Todd A, Sharp L. Routes to Diagnosis in Lung Cancer—Do Socio-Demographics Matter? An English Population-Based Study. Cancers 2025, 17(11), 1874.
  • Hochmair M, Schenker M, Cobo Dols M, Kim TM, Ozyilkan O, Smagina M, Leonova V, Kato T, Fedenko A, De Angelis F, Rittmeyer A, Gray JE, Greystoke A, Aggarwal H, Huang Q, Zhao B, Lara-Guerra H, Nadal E. Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy. Journal of Thoracic Oncology 2025, 20(2), 203-218.
  • Lee SM, Hewish M, Ahmed S, Papadatos-Pastos D, Karapanagiotou E, Blackhall F, Ford A, Young R, Garcia A, Arora A, Hollingdale A, Ahmad T, Forster M, Greystoke A, Bremner F, Rudd R, Farrelly L, Vaja S, Hackshaw A. Hydroxychloroquine in combination with platinum doublet chemotherapy as first-line treatment for extensive-stage small cell lung cancer (Study 15): A randomised phase II multicentre trial. European Journal of Cancer 2025, 215, 115162.
  • Crowe L, Brown MC, Lecouturier J, Greystoke A, Nuryunarsih D, Rimmer B, Bojke A, Bojke R, Richardson J, Wells M, Ezeala E, Carter L, Todd A, Sharp L. Development of the SCNS-TARGET: a new tool to assess unmet needs in cancer patients utilising immuno-, biological or precision therapies. Journal of Cancer Survivorship 2025, epub ahead of print.
  • Elliott K, Haworth E, Bolnykh I, McAllister-Williams HR, Greystoke A, Todd A, Sharp L. Breast cancer patients with a pre-existing mental illness are less likely to receive guideline-recommended cancer treatment: a systematic review and meta-analysis. The Breast 2025, 79, 103855.
  • Gulati P, Carruthers V, Hutton C, Cassidy C, Amankwatia EB, Pascual S, Florence E, Gebru TG, Jorgensen AL, Greystoke A, Makin G, McCabe MG, Hawcutt DB, Veal GJ, Jamieson D. An assessment of circulating biomarkers and germline genetic variants in predicting chemotherapy associated mucositis in Ewing sarcoma. EJC Paediatric Oncology 2025, 5, 100216.
  • Norris RP, Dew R, Greystoke A, Cresti N, Cain H, Todd A, Sharp L. Sociodemographic Disparities in HER2⁺ Breast Cancer Trastuzumab Receipt: An English Population-Based Study. CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION 2024, 33(10), 1298-1310.
  • Rae S, Shaya S, Taylor E, Hoben J, Oluwashegun D, Lowe H, Haris N, Bashir S, Oing C, Krebs MG, Thistlethwaite FC, Carter L, Cook N, Greystoke A, Graham DM, Plummer R. Social determinants of health inequalities in early phase clinical trials in Northern England. British Journal of Cancer 2024, 131, 685-691.
  • Bashir B, Wang JS, Falchook G, Fontana E, Arkenau H-T, Carter L, Galot R, Basu B, Greystoke A, Subbiah V, Richardson DL, Orr H, Bennett G, Sharma R, Xu H, Paganoni P, Xu C, Campbell C, McKean M. Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors. Journal of Clinical Oncology 2024, 42(29), 3443-3452.
  • Gault A, Hogarth L, Williams KC, Greystoke A, Rajan N, Speight A, Lamb CA, Bridgewood A, Brown-Schofield LJ, Rayner F, Isaacs JD, Nsengimana J, Stewart CJ, Anderson AE, Plummer R, Pratt AG. Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort study. BMC Cancer 2024, 24(1), 733.
  • Wheatley DA, Berardi R, Climent Duran MA, Tomiak A, Greystoke AP, Joshua AM, Arkenau H-T, Geczi L, Corbacho JG, Paz-Ares LG, Hussain SA, Petruzelka L, Delmonte A, Chappey C, Masters JC, Michelon E, Murphy DA, Mwewa S, Cesari R, Doger de Speville B. First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study. Cancer Research Communications 2024, 4(6), 1609-1619.
  • Messina C, Giunta EF, Signori A, Rebuzzi SE, Banna GL, Maniam A, Buti S, Cattrini C, Fornarini G, Bauckneht M, Greystoke A, Plummer R, Oing C, Rescigno P. Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis. European Urology Oncology 2024, 7(2), 179-188.
  • Juric D, Barve M, Vaishampayan U, Roda D, Calvo A, Janez NM, Trigo J, Greystoke A, Harvey RD, Olszanski AJ, Opyrchal M, Spira A, Thistlethwaite F, Jimenez B, Sappal JH, Kannan K, Riley J, Li C, Li C, Gregory RC, Miao H, Wang S. A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors. Cancer Medicine 2024, 13(5).
  • Crowe L, Brown M, Lecouturier J, Greystoke A, Bojke A, Bojke R, Richardson J, Wells M, Ezeala E, Carter L, Sharp L, Todd A. “Oh when’s your treatment ending?” “Never!” The unmet needs of cancer patients treated with immuno-, biological and precision therapies: a qualitative interview study. European Journal of Oncology Nursing 2024, 73, 102696.
  • Norris RP, Dew R, Greystoke A, Todd A, Sharp L. Socio-economic Inequalities in Novel NSCLC Treatments During the Era of Tumor Biomarker Guided Therapy: A Population-based Cohort Study in a Publicly Funded Healthcare System. Journal of Thoracic Oncology 2023, 18(8), 990-1002.
  • Rae S, Plummer E, Fitzgerald L, Hogarth L, Bridgewood A, Brown-Schofield L, Graham J, Haigh S, McAnulty C, Drew Y, Haris N, Bashir S, Plummer R, Greystoke A. Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders. Journal of Cancer Research and Clinical Oncology 2023, 149, 16355–16363.
  • Crowe L, Brown M, Bojke A, Bojke R, Greystoke A, Lecouturier J, Richardson J, Wells M, Todd A, Sharp L. Assessing the unmet needs of patients with advanced cancer treated by biological and precision therapies: protocol for TARGET, a mixed methods study. BMJ Open 2023, 13, e066229.
  • Halford S, Veal GJ, Wedge SR, Payne GS, Bacon CM, Sloan P, Dragoni I, Heinzmann K, Potter S, Salisbury BM, Chenard-Poirier M, Greystoke A, Howell EC, Innes WA, Morris K, Plummer C, Rata M, Petrides G, Keun HC, Banerji U, Plummer R. A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer. Clinical Cancer Research 2023, 29(8), 1429-1439.
  • Welford J, Rafferty R, Hunt K, Short D, Duncan L, Ward A, Rushton C, Todd A, Nair S, Hoather T, Clarke M, Dawes L, Dawson F, Anderson V, Pelham A, Lowe H, Dewhurst F, Greystoke A. The Clinical Frailty Scale can indicate prognosis and care requirements on discharge in oncology and haemato-oncology inpatients: A cohort study. European Journal of Cancer Care 2022, 31(6), e13752.
  • Zucali PA, Lin C-C, Carthon BC, Bauer TM, Tucci M, Italiano A, Iacovelli R, Su W-C, Massard C, Saleh M, Daniele G, Greystoke A, Gutierrez M, Pant S, Shen Y-C, Perrino M, Meng R, Abbadessa G, Lee H, Dong Y, Chiron M, Wang R, Loumagne L, Lepine L, de Bono J. Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study. Journal for immunoTherapy of cancer 2022, 10(1), e003697.
  • Walker K, Hinsley S, Phillip R, Oughton JB, Murden G, Chalmers AJ, Faivre-Finn C, Greystoke A, Brown SR, Forster M, Franks K, Gilbert A, Hanna GG, Hannaway N, Harrow S, Haswell T, Hiley C, Krebs M, Salem A, Sebag-Montefiore D, Shaw P, Twelves C, Walls G, Young R. Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations-CONCORDE. JCO Precision Oncology 2022, 6, e2200133.
  • Cooper M, Chmelo J, Sinclair RCF, Charman S, Hallsworth K, Welford J, Phillips AW, Greystoke A, Avery L. Exploring factors influencing uptake and adherence to a home-based prehabilitation physical activity and exercise intervention for patients undergoing chemotherapy before major surgery (ChemoFit): a qualitative study. BMJ Open 2022, 12(9), e062526.
  • Chmelo J, Phillips AW, Greystoke A, Charman SJ, Avery L, Hallsworth K, Welford J, Cooper M, Sinclair RCF. A feasibility trial of prehabilitation before oesophagogastric cancer surgery using a multi-component home-based exercise programme: the ChemoFit study. Pilot and Feasibility Studies 2022, 8(1), 173.
  • Harvie M, Pegington M, Howell SJ, Bundred N, Foden P, Adams J, Graves L, Greystoke A, Mattson MP, Cutler RG, Williamson J, Livingstone K, McMullen D, Sellers K, Lombardelli C, Cooper G, McDiarmid S, Howell A. Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer. British Journal of Cancer 2021.
  • Chmelo J, Phillips AW, Greystoke A, Bradshaw A, Sinclair RCF. Comparison of the effects of FLOT and ECX chemotherapy for oesophagogastric adenocarcinoma on cardiopulmonary reserve. British Journal of Surgery 2021, 108(10), e328-e329.
  • Middleton G, Fletcher P, Popat S, Savage J, Summers Y, Greystoke A, Gilligan D, Cave J, O'Rourke N, Brewster A, Toy E, Spicer J, Jain P, Dangoor A, MacKean M, Forster M, Farley A, Wherton D, Mehmi M, Sharpe R, Mills TC, Cerone MA, Yap TA, Watkins TBK, Lim E, Swanton C, Billingham L. The National Lung Matrix Trial of personalised therapy in lung cancer. Nature 2020, 583, 807-812.
  • Gomes F, Lewis A, Morris R, Parks R, Kalsi T, Babic-Illamn G, Baxter M, Colquhoun K, Rodgers L, Smith E, Greystoke A, Bayman N, Cree A, Ng C, DE Liguori Carino N, Basile S, Moore J, Merchant Z, Swinson D, Parbhoo A, Jones R, Davies E, Danson SJ, Young R, Morgan J, Wyld L, Corrie PG, Doherty GJ, Crawford K, Wright J, Reed M, Ugolini F, Lind M, Cheung K-L, Harari D, Simcock R. The care of older cancer patients in the United Kingdom. ecancermedicalscience 2020, 14, 1101.
  • Walls GM, Oughton JB, Chalmers AJ, Brown S, Collinson F, Forster MD, Franks KN, Gilbert A, Hanna GG, Hannaway N, Harrow S, Haswell T, Hiley CT, Hinsley S, Krebs M, Murden G, Phillip R, Ryan AJ, Salem A, Sebag-Montefoire D, Shaw P, Twelves CJ, Walker K, Young RJ, Faivre-Finn C, Greystoke A. CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. Clinical and Translational Radiation Oncology 2020, 25, 61-66.
  • Norris R, Dew R, Sharp L, Greystoke A, Rice S, Johnell K, Todd A. Are there socio-economic inequalities in utilization of predictive biomarker tests and biological and precision therapies for cancer? A systematic review and meta-analysis. BMC Medicine 2020, 18, 282.
  • Chmelo J, Phillips AW, Greystoke A, Charman SJ, Avery L, Hallsworth K, Welford J, Sinclair RCF. A feasibility study to investigate the utility of a home-based exercise intervention during and after neo-adjuvant chemotherapy for oesophago-gastric cancer-the ChemoFit study protocol. Pilot and Feasibility Studies 2020, 6(1), 50.
  • Evans TRJ, Dean E, Molife LR, Lopez J, Ranson M, El-Khouly F, Zubairi I, Savulsky C, Reyderman L, Jia Y, Sweeting L, Greystoke A, Barriuso J, Kristeleit R. Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomalformulation in patients with solid tumours. British Journal of Cancer 2019, 120(4), 379–386.
  • Iqbal MS, Atherton P, Macgregor C, Wieczorek A, Singer J, Walther J, Little F, Harden S, Peedell C, Cyriac A, Chowdhury S, Bayne M, Yip K, Britten A, Powell C, Brock J, Datta S, Sevitt T, Mehta A, Greystoke A. Implications for UK practice of the use of durvalumab in stage III NSCLC. Annals of Oncology 2019, 30(2), ii36-ii36.
  • Coomer AO, Black F, Greystoke A, Munkley J, Elliott DJ. Alternative splicing in lung cancer. Biochimica et Biophysica Acta - Gene Regulatory Mechanisms 2019, 1862(11-12), 194388.
  • Mak G, Soria J-C, Blagden SP, Plummer R, Fleming RA, Nebot N, Zhang J, Mazumdar J, Rogan D, Gazzah A, Rizzuto I, Greystoke A, Yan L, Tolson J, Auger KR, Arkenau H-T. A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours. British Journal of Cancer 2019, 120, 975-981.
  • Gomes F, Tokaca N, Yip K, Ghosh S, Newsom-Davis T, Greystoke A, Mills H, Ahmed S, Harle AS, Ayre G, Shah R, Popat S, Blackhall FH, Summers Y. 140P - Brigatinib experience on the ALK project. Annals of Oncology 2019, 30(Supplement 2), ii53.
  • Ahn M-J, Chiu C-H, Cheng Y, Han J-Y, Goldberg SB, Greystoke A, Crawford J, Zhao Y, Huang X, Johnson M, Vishwanathan K, Mendoza-Naranjo A, Mok TSK. 105O - Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study. Annals of Oncology 2019, 30(Supplement 2), ii48.
  • Perthen JE, Ali T, McCulloch D, Navidi M, Phillips AW, Sinclair RCF, Griffin SM, Greystoke A, Petrides G. Intra- and Interobserver Variability in Skeletal Muscle Measurements using Computed Tomography Images. European Journal of Radiology 2018, 109, 142-146.
  • Navidi M, Phillips AW, Griffin SM, Duffield KE, Greystoke A, Sumpter K, Sinclair RCF. Cardiopulmonary fitness before and after neoadjuvant chemotherapy in patients with oesophagogastric cancer. British Journal of Surgery 2018, 105(7), 900-906.
  • Greystoke A, Steele N, Arkenau H-T, Blackhall F, Md Haris N, Lindsay CR, Califano R, Voskoboynik M, Summers Y, So K, Ghiorghiu D, Dymond AW, Hossack S, Plummer R, Dean E. SELECT-3: A phase i study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting. British Journal of Cancer 2017, 117(7), 938-946.
  • Cho BC, Kim D-W, Bearz A, Laurie SA, McKeage M, Borra G, Park K, Kim S-W, Ghosn M, Ardizzoni A, Maiello E, Greystoke A, Yu R, Osborne K, Gu W, Scott JW, Passos VQ, Lau YY, Wrona A. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology 2017, 12(9), 1357-1367.
  • Greystoke A, Ayub M, Rothwell DG, Morris D, Burt D, Hodgkinson CL, Morrow CJ, Smith N, Aung K, Valle J, Carter L, Blackhall F, Dive C, Brady G. Development of a circulating miRNA assay to monitor tumor burden: From mouse to man. Molecular Oncology 2016, 10(2), 282-291.
  • Jamieson D, Griffin MJ, Sludden J, Drew Y, Cresti N, Swales K, Merriman M, Allen R, Bevan P, Buerkle M, Mala C, Coyle V, Rodgers L, Dean E, Greystoke A, Banerji U, Wilson RH, Evans TRJ, Anthoney A, Ranson M, Boddy AV, Plummer R. A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours. European Journal of Cancer 2016, 68, 1-10.
  • Iqbal MS, Paleri V, Brown J, Greystoke A, Dobrowsky W, Kelly C, Kovarik J. Spindle cell carcinoma of the head and neck region: Treatment and outcomes of 15 patients. ecancermedicalscience 2015, 9, 594.
  • Basu B, Dean E, Pugilisi M, Greystoke A, Ong M, Burke W, Harrington L, Green S, Olemann E, DeBono JS, Ranson M, Banerji U. First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014. Clinical Cancer Research 2015, 21(15), 3412-3419.
  • Greystoke A, Ayub M, Rothwell D, Morris D, Smith N, Carter L, Metcalf R, Blackhall F, Dive C, Brady G. Development of a Circulating miRNA Assay to Monitor Tumour Burden: from Mouse to Man. Cancer Research 2015. Submitted.
  • Hodgkinson CL, Morrow CJ, Li Y, Metcalf RL, Rothwell DG, Trapani F, Polanski R, Burt DJ, Simpson KL, Morris K, Pepper SD, Nonaka D, Greystoke A, Kelly P, Bola B, Krebs MG, Antonello J, Ayub M, Faulkner S, Priest L, Carter L, Tate C, Miller CJ, Blackhall F, Brady G, Dive C. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nature Medicine 2014, 20(8), 897-903.
  • Molife LR, Dean E, BlancoCodesido M, Krebs MG, Brunetto A, Greystoke AP, Daniele G, Lee L, Kuznetsov G, Myint KT, deLasHeras B, Wood K, Ranson MR. A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors. Clinical Cancer Research 2014, 20(24), 6284-6294.
  • Greystoke A, Harris G, Jenkins M, Goonetilleke D, Moore D, Lancashire M, Ranson M, Hughes A, Clack G, Dive C. Assessment of diurnal changes and confounding factors that affect circulating cell death biomarker levels: A short communication. Journal of Pharmaceutical and Biomedical Analysis 2013, 84, 184-188.
  • Gibb A, Greystoke A, Ranson M, Linton K, Neeson S, Hampson G, Illidge T, Smith E, Dive C, Pettitt A, Lister A, Johnson P, Radford J. A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity. British Journal of Cancer 2013, 109(10), 2560-2565.
  • Bouranis L, Sperrin M, Greystoke A, Dive C, Renehan AG. 0 0 1 10 57 NICR, Newcastle University 1 1 66 14.0 96 800x600 Normal 0 false false false EN-GB JA X-NONE The interaction between prognostic and pharmaco-dynamic biomarkers. British Journal of Cancer 2013, 109(7), 1782-5. In Preparation.
  • Greystoke A, Dean E, Saunders MP, Cummings J, Hughes A, Ranson M, Dive C, Renehan AG. Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer. British Journal of Cancer 2012, 107(9), 1518-1524.
  • Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, Ward T, Blackhall FH, Dive C. Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer. Journal of Clinical Oncology 2012, 30(5), 525-532.
  • Moore DJ, Greystoke A, Butt F, Wurther J, Growcott J, Hughes A, Dive C. A Pilot Study Assessing the Prognostic Value of CK18 and nDNA Biomarkers in Severe Sepsis Patients. Clinical Drugs Investigation 2012, 32(3), 179-187.
  • Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, Ferraldeschi R, Hughes A, Clack G, Dive C, Blackhall FH. 0 0 1 22 130 NICR, Newcastle University 1 1 151 14.0 96 800x600 Normal 0 false false false EN-GB JA X-NONE Evaluation and prognostic significance of circulating tumour cells in patients with non small cell lung cancer (NSCLC). Journal of Clinical Oncology 2011, 29(12), 1556-63.
  • Khan OA, Gore M, Lorigan P, Stone J, Greystoke A, Burke W, Carmichael J, Watson AJ, McGown G, Thorncroft M, Margison GP, Califano R, Larkin J, Wellman S, Middleton MR. 0 0 1 20 118 NICR, Newcastle University 1 1 137 14.0 96 800x600 Normal 0 false false false EN-GB JA X-NONE A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. British Journal of Cancer 2011, 104(5), 750-5.
  • Greystoke A, OConnor JPB, Linton K, Taylor MB, Cummings J, Ward T, Hughes A, Maders F, Ranson M, Radford JA, Dive C. 0 0 1 15 88 NICR, Newcastle University 1 1 102 14.0 96 800x600 Normal 0 false false false EN-GB JA X-NONE Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. British Journal of Cancer 2011, 104(4), 719-25. In Preparation.
  • Brookes K, Cummings J, Backen A, Greystoke A, Ward T, Jayson GC, Dive C. Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs. British Journal of Cancer 2010, 102(10), 1524-32.
  • Greystoke A, Jodrell DI, Cheung M, Rivans I, Mackean MJ. How many cisplatin administration protocols does your department use?. European Journal of Cancer Care 2010, 19(1), 80-90.
  • Board RE, Wardley AM, Dixon JM, Armstrong AC, Howell S, Renshaw L, Donald E, Greystoke A, Ranson M, Hughes A, Dive C. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Research and Treatment 2010, 120(2), 461-7.
  • Hou JM, Greystoke A, Lancashire L, Cummings J, Ward T, Board R, Amir E, Hughes S, Krebs M, Hughes A, Ranson M, Lorigan P, Dive C, Blackhall FH. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. 175 2009, 2, 808-16.
  • Greystoke A, Cummings J, Ward T, Simpson K, Renehan A, Butt F, Moore D, Gietema J, Blackhall F, Ranson M, Hughes A, Dive C. Optimisation of circulating biomarkers of cell death for routine clinical use. Annals of Oncology 2008, 19(5), 990-5. In Preparation.
  • Board RE, Williams VS, Knight L, Shaw J, Greystoke A, Ranson M, Dive C, Blackhall FH, Hughes A. Isolation and extraction of circulating tumor DNA from patients with small cell lung cancer. Annals of New York Academy of Science 2008, 1137, 98.
  • Greystoke A, Blagden S, Thomas AL, Scott E, Attard G, Molife R, Vidal L, Pacey S, Sarkar D, Jenner A, DeBono JS, Steward W. A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of athree-weekly cycle in combination with carboplatin given on day 1 alone inpatients with advanced solid tumours. Annals of Oncology 2006, 17(8), 1313-9.

• Conference Proceedings (inc. Abstracts)

  • Norris RP, Dew R, Greystoke A, Todd A, Sharp L. OP42 Socio-economic inequalities in novel NSCLC treatments during the era of tumour biomarker guided therapy: a population-based cohort study. In: Society for Social Medicine & Population Health 67th Annual Scientific meeting. 2023, Journal of Epidemiology and Community Health.
  • Norris RP, Fuller E, Greystoke A, Todd A, Sharp L. OP41 Routes to diagnosis in lung cancer – do socio-demographics matter? An English population-based study. In: Society for Social Medicine & Population Health 67th Annual Scientific meeting. 2023, Newcastle upon Tyne: BMJ.
  • Norris RP, Dew R, Todd A, Greystoke A, Sharp L. OA01.05 Socio-economic Inequalities in NSCLC Treatment During the Era of Tumour Biomarker Guided Therapy: A Population-based Study. In: 2022 World Conference on Lung Cancer. 2022, Vienna, Austria: Elsevier.
  • Greystoke A, Hogarth L, Patterson M, Williams I, Ness T, Georgiadis K, Bolt L, Bettison I, Turner D, Jamieson D, Simmons T, Hughes A, Jaedicke K, Gardiner J, Mulvenna P, Leaning D, Bradshaw A, Butler R, Black F. The introduction of the Cancer Research UK Stratified Medicine Programme 2 (CRUK SMP2) in North East England; lessons learned and experience gained. In: 14th Annual British Thoracic Oncology Group Conference 2016. 2016, Dublin, Ireland: Elsevier.
  • Dean E, Steele N, Arkenau HT, Blackhall F, Haris NM, Lindsay C, Rafii S, Califano R, Plummer R, Voskoboynik M, Summers YJ, Ghiorghiu D, Dymond A, So K, Greystoke A. SELECT-3: A phase I study of selumetinib in combination with platinum doublet chemotherapy for advanced NSCLC in the first-line setting. In: 41st ESMO Congress (ESMO 2016). 2016, Copenhagen, Denmark: Oxford University Press.
  • Hall S, Lambourne B, Aynsley E, Gardiner J, Greystoke A, Hughes A, Jones C, Leaning D, Li L, Mansy T, Margetts J, Mcdonald F, Mcmenemin R, Mulvenna P, Peedell C, Shakespeare D, Simmons T, Singhal S, Turnbull H. Crizotinib in clinical practice: the North East of England's experience. In: 14th Annual British Thoracic Oncology Group Conference 2016. 2016, Dublin, Ireland: Elsevier Ireland Ltd.
  • Wyatt N, Hogarth L, Turner D, Patterson M, Jamieson D, Black F, Hutton C, Mulvenna P, Simmons T, Bradshaw A, Kolenda C, Parker C, Martin-Ruiz C, Greystoke A. Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). In: IASLC 17th World Conference on Lung Cancer. 2016, Vienna, Austria: Elsevier.
  • Arkenau HT, Gazzah A, Plummer R, Blagden SP, Mak G, Soria JC, Greystoke A, Rizzuto I, Rogan D, Mazumdar J, Laubscher K, Auger KR, Swartz LS, Mattern ML, Nebot N, Singh RP, Fleming RA, Yan L. A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors. In: American Society of Clinical Oncology (ASCO) 2015 Annual Meeting. 2015, Chicago, Illinois, USA: American Society of Clinical Oncology.
  • Roda D, Drew Y, Azaro A, Smith AD, Greystoke A, Sicart E, Escriba PV, Busquets X, Llado V, Tur V, Klumper E, Ahnert JR, Molife LR, Plummer R. A first-in-human dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of oral 2-hydroxyoleic acid (2-OHOA) in adult patients (pt) with advanced solid tumors including grade III/IV glioblastoma multiforme (GBM). In: 2015 American Society of Clinical Oncology Annual Meeting. 2015, Chicago, Illinois, USA: American Society of Clinical Oncology.
  • Vidal L, Leslie M, Sludden J, Griffin MG, Plummer R, Judson I, Lee C, Greystoke A, Calvert AH, Boddy AV. A phase I and pharmacodynamic study of a 7 day infusion schedule of the DNMT1 antisense compound MG98. In: 42nd Meeting of the American Society of Clinical Oncology Annual Meeting Proceedings. 2005, Orlando, Florida, USA: Journal of Clinical Oncology, American Society of Clinical Oncology.

• Editorials

  • Greystoke A, Chaturvedi A. An Introduction to Stratified Medicine. Drug Discovery Today 2015, 20(12), 1409-1413.
  • Greystoke A, Ranson M. Learning from toxicity patterns in phase I trials during the era of mechanism targeted agents. Annals of Oncology 2012, 23(8), 1934-1936.

• Reviews

  • Gomes F, Farrington N, Pearce J, Swinson D, Welford J, Greystoke A, Baxter M, Brown-Kerr AG, Wyld L, Morgan J, Battisti NML, Barrell A, Cobben D, Cree A, Johnston M, Colquhoun K, Phillips I, Smith J, Stapley S, Lyons L, Balachandran K, Brown H, Bryce R, Dacie R, Parks R, Denholm M, Harari D, Rigden T, Sommer D, Williams K, Worby K, Cheung K-L. The care of older patients with cancer across the United Kingdom in 2024: A narrative review by the International Society of Geriatric Oncology UK Country Group. Journal of Geriatric Oncology 2025, 16(1), 102133.
  • Decoster L, Camidge DR, Fletcher JA, Addeo A, Greystoke A, Kantilal K, Game LB, Kanesvaran R, Gomes F. Targeted therapy for older patients with an oncogene driven non-small cell lung cancer: Recommendations from a SIOG expert group. Lung Cancer 2025, 200, 108087.
  • Aldea M, Rotow JK, Arcila M, Hatton M, Sholl L, Rolfo C, Tagliamento M, Radonic T, Schalper KA, Subbiah V, Malapelle U, Roden AC, Manochakian R, Tsao M-S, Linardou H, Hui R, Novello S, Greystoke A, Saqi A, Lantuejoul S, Hwang DM, Nevins K, Wynes M, Waqar S, Han Y, Yatabe Y, Chang W-C, Hayashi T, Kim T-J, Hofman P, Tavora F, Hirsch FR, Denninghoff V, Leighl NB, Drilon A, Cooper WA, Dacic S, Mohindra P, Pavlakis N, Lopez-Rios F. Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer. Journal of Thoracic Oncology 2025, Epub ahead of print.
  • D'Arcangelo M, Margetts J, Greystoke A. The use of circulating biomarkers in early clinical trials in patients with cancer. Biomarkers in Medicine 2015, 9(10), 1011-1023.
  • Greystoke A, Mullamitha SA. How Many Diseases Are Colorectal Cancer?. Gastroenterology Research and Practice 2012, 2012, 564741.
  • Dean E, Greystoke A, Ranson M, Dive C. Biomarkers of cell death applicable to early clinical trials. Experimental Cell Research 2012, 318(11), 1252-1259.